Category
103 articles — page 3 of 9
Afamelanotide is a synthetic melanocortin analogue approved in Europe for a different condition, but studied as a phototherapy enhancer in vitiligo. The data shows meaningful benefit when combined with NbUVB. Here is what we know.
Alpha lipoic acid has been studied in combination with phototherapy for vitiligo in small trials showing modest benefit. Here is what the evidence actually says and where it fits in a rational treatment plan.
Baricitinib is an oral JAK1/2 inhibitor approved for alopecia areata and rheumatoid arthritis with emerging Phase 3 data for vitiligo. Here is what the trial evidence shows and how it compares to other JAK inhibitors.
There is no permanent cure for vitiligo — but that is not the full picture. Meaningful repigmentation, long-term remission, and a dramatically improved appearance are all achievable with current treatments. Here is the honest answer.
Yes — repigmented vitiligo can depigment again after treatment stops. Understanding relapse rates, what drives recurrence, and how to maintain results with the minimum ongoing intervention.
Excimer laser therapy delivers targeted narrowband UVB to specific vitiligo patches, producing better results for limited disease than whole-body phototherapy — but at higher cost and limited availability. Here is the complete picture.
Vitiligo changes slowly — slowly enough that without consistent documentation you cannot tell whether treatment is working. Here is a practical system for tracking patches, understanding clinical scoring tools, and setting realistic timelines.
Surgical melanocyte transplantation is the most effective option for stable vitiligo that has not responded to medical treatment — particularly in areas with depleted follicular reserves. Here is how it works, who qualifies, and what outcomes look like.
Minocycline is a tetracycline antibiotic used off-label for vitiligo because of its anti-inflammatory and immunomodulatory properties — not its antibiotic effect. The evidence is limited but the rationale is plausible. Here is the honest picture.
Narrowband UVB and excimer laser both emit 308nm therapeutic UV but deliver it very differently. Choosing between them depends on how much of your body is affected, your access to equipment, and your budget. Here is the head-to-head comparison.
The three main topical approaches to vitiligo — JAK inhibitor (Opzelura), calcineurin inhibitor (tacrolimus), and corticosteroids — each have different mechanisms, evidence levels, side effects, and appropriate uses. Here is the complete comparison.
Polypodium leucotomos is an oral fern extract with antioxidant and photoprotective properties. The evidence base for its use as a phototherapy adjunct in vitiligo is modest but real — here is what the trials actually show.
